These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 24023670)
1. Is upregulation of BCL2 a determinant of tumor development driven by inactivation of CDH1/E-cadherin? Karch I; Schipper E; Christgen H; Kreipe H; Lehmann U; Christgen M PLoS One; 2013; 8(8):e73062. PubMed ID: 24023670 [TBL] [Abstract][Full Text] [Related]
2. E-cadherin to P-cadherin switching in lobular breast cancer with tubular elements. Christgen M; Bartels S; van Luttikhuizen JL; Bublitz J; Rieger LU; Christgen H; Stark H; Sander B; Lehmann U; Steinemann D; Derksen PWB; Kreipe H Mod Pathol; 2020 Dec; 33(12):2483-2498. PubMed ID: 32572153 [TBL] [Abstract][Full Text] [Related]
3. Comprehensive genetic and functional characterization of IPH-926: a novel CDH1-null tumour cell line from human lobular breast cancer. Christgen M; Bruchhardt H; Hadamitzky C; Rudolph C; Steinemann D; Gadzicki D; Hasemeier B; Römermann D; Focken T; Krech T; Ballmaier M; Schlegelberger B; Kreipe H; Lehmann U J Pathol; 2009 Apr; 217(5):620-32. PubMed ID: 19191266 [TBL] [Abstract][Full Text] [Related]
4. Epigenetic silencing in non-neoplastic epithelia identifies E-cadherin (CDH1) as a target for chemoprevention of lobular neoplasia. Zou D; Yoon HS; Perez D; Weeks RJ; Guilford P; Humar B J Pathol; 2009 Jun; 218(2):265-72. PubMed ID: 19294736 [TBL] [Abstract][Full Text] [Related]
5. E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis. Vos CB; Cleton-Jansen AM; Berx G; de Leeuw WJ; ter Haar NT; van Roy F; Cornelisse CJ; Peterse JL; van de Vijver MJ Br J Cancer; 1997; 76(9):1131-3. PubMed ID: 9365159 [TBL] [Abstract][Full Text] [Related]
6. Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. De Leeuw WJ; Berx G; Vos CB; Peterse JL; Van de Vijver MJ; Litvinov S; Van Roy F; Cornelisse CJ; Cleton-Jansen AM J Pathol; 1997 Dec; 183(4):404-11. PubMed ID: 9496256 [TBL] [Abstract][Full Text] [Related]
7. Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. Acs G; Lawton TJ; Rebbeck TR; LiVolsi VA; Zhang PJ Am J Clin Pathol; 2001 Jan; 115(1):85-98. PubMed ID: 11190811 [TBL] [Abstract][Full Text] [Related]
8. Lobular breast cancer: Clinical, molecular and morphological characteristics. Christgen M; Steinemann D; Kühnle E; Länger F; Gluz O; Harbeck N; Kreipe H Pathol Res Pract; 2016 Jul; 212(7):583-97. PubMed ID: 27233940 [TBL] [Abstract][Full Text] [Related]
9. [Expression of Twist, E-cadherin and N-cadherin in breast carcinoma and their clinical significance]. Ma YH; Wang K; Li L; Lu ZH; Chen J Zhonghua Bing Li Xue Za Zhi; 2010 Jan; 39(1):5-9. PubMed ID: 20388391 [TBL] [Abstract][Full Text] [Related]
10. CDH1 promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer. Caldeira JR; Prando EC; Quevedo FC; Neto FA; Rainho CA; Rogatto SR BMC Cancer; 2006 Mar; 6():48. PubMed ID: 16512896 [TBL] [Abstract][Full Text] [Related]
11. E-Cadherin Mutational Landscape and Outcomes in Breast Invasive Lobular Carcinoma. Djerroudi L; Bendali A; Fuhrmann L; Benoist C; Pierron G; Masliah-Planchon J; Kieffer Y; Carton M; Tille JC; Cyrta J; Ramtohul T; Bonneau C; Caly M; Renault V; Bidard FC; Mechta-Grigoriou F; Vincent-Salomon A Mod Pathol; 2024 Oct; 37(10):100570. PubMed ID: 39025406 [TBL] [Abstract][Full Text] [Related]
12. Carcinomas in situ of the breast with indeterminate features: role of E-cadherin staining in categorization. Jacobs TW; Pliss N; Kouria G; Schnitt SJ Am J Surg Pathol; 2001 Feb; 25(2):229-36. PubMed ID: 11176072 [TBL] [Abstract][Full Text] [Related]
13. Cadherin-catenin complex dissociation in lobular neoplasia of the breast. Morrogh M; Andrade VP; Giri D; Sakr RA; Paik W; Qin LX; Arroyo CD; Brogi E; Morrow M; King TA Breast Cancer Res Treat; 2012 Apr; 132(2):641-52. PubMed ID: 22080244 [TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic implications of E-cadherin reactivity in patients with lobular carcinoma in situ of the breast. Goldstein NS; Kestin LL; Vicini FA Cancer; 2001 Aug; 92(4):738-47. PubMed ID: 11550142 [TBL] [Abstract][Full Text] [Related]
15. αE-catenin is a candidate tumor suppressor for the development of E-cadherin-expressing lobular-type breast cancer. de Groot JS; Ratze MA; van Amersfoort M; Eisemann T; Vlug EJ; Niklaas MT; Chin SF; Caldas C; van Diest PJ; Jonkers J; de Rooij J; Derksen PW J Pathol; 2018 Aug; 245(4):456-467. PubMed ID: 29774524 [TBL] [Abstract][Full Text] [Related]
16. Interobserver variability and aberrant E-cadherin immunostaining of lobular neoplasia and infiltrating lobular carcinoma. Choi YJ; Pinto MM; Hao L; Riba AK Mod Pathol; 2008 Oct; 21(10):1224-37. PubMed ID: 18587329 [TBL] [Abstract][Full Text] [Related]
17. Disparate E-cadherin mutations in LCIS and associated invasive breast carcinomas. Rieger-Christ KM; Pezza JA; Dugan JM; Braasch JW; Hughes KS; Summerhayes IC Mol Pathol; 2001 Apr; 54(2):91-7. PubMed ID: 11322170 [TBL] [Abstract][Full Text] [Related]
18. Insights into E-Cadherin Impairment in Uchida S; Sugino T Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201647 [TBL] [Abstract][Full Text] [Related]
19. Frequent E-cadherin gene inactivation by loss of heterozygosity in pleomorphic lobular carcinoma of the breast. Palacios J; Sarrió D; García-Macias MC; Bryant B; Sobel ME; Merino MJ Mod Pathol; 2003 Jul; 16(7):674-8. PubMed ID: 12861063 [TBL] [Abstract][Full Text] [Related]
20. Loss of expression and aberrant methylation of the CDH1 (E-cadherin) gene in breast cancer patients from Kashmir. Asiaf A; Ahmad ST; Aziz SA; Malik AA; Rasool Z; Masood A; Zargar MA Asian Pac J Cancer Prev; 2014; 15(15):6397-403. PubMed ID: 25124632 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]